Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.37 |
| ▸ | MERTK | Q12866 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14018784 | 1.00 | MAPK14 (0.39) | MAPK14AXLTYRO3MERTKMET | |
| SCHEMBL4832715 | 0.93 | SCN9A (0.35) | MAPK14AXLTYRO3MERTKMET | |
| SCHEMBL14018797 | 0.93 | SCN9A (0.35) | MAPK14AXLTYRO3MERTKMET | |
| SCHEMBL4836387 | 0.91 | MAPK14 (0.39) | MAPK14MAPK11TRPA1 | |
| SCHEMBL14018823 | 0.91 | MAPK14 (0.37) | MAPK14AXLTYRO3MERTKMET | |
| SCHEMBL4841136 | 0.91 | MAPK14 (0.37) | MAPK14AXLTYRO3MERTKMET | |
| SCHEMBL14018819 | 0.91 | MAPK14 (0.42) | MAPK14AXLTYRO3MERTKMET | |
| SCHEMBL4017603 | 0.91 | MAPK14 (0.42) | MAPK14AXLTYRO3MERTKMET | |
| SCHEMBL4017610 | 0.91 | MAPK14 (0.42) | MAPK14AXLTYRO3MERTKMET | |
| SCHEMBL14018843 | 0.89 | MAPK14 (0.41) | MAPK14AXLTYRO3MERTKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | claimed |
| US-7608603-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1919914-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| WO-2007023115-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1737865-A1 | FUSED DERIVATIVES OF PYRAZOLE | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005085249-A1 | FUSED DERIVATIVES OF PYRAZOLE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | MAPK14 70/4885AXL 493/4885TYRO3 442/4885 |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAPK9, MAPK3 | MAPK14 22/4885AXL 1795/4885TYRO3 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.